论文部分内容阅读
瑞典中部骨髓瘤研究组采用前瞻性随机研究比较了VMCP/VBAP交替联合化疗和MP方案对Ⅲ期多发性骨髓瘤(MM)的疗效.86例初治Ⅲ期MM患者随机分为两组:1.VMCP/VBAP组42例,交替使用VMCP和VBAP方案,间歇期3周,生效后延长至6周.VMCP方案包括长春新碱1mg静注第1天,马法兰5mg/m~2/天,
The Central Swedish Myeloma Study Group, a prospective, randomized study, compared the efficacy of the VMCP / VBAP alternated chemotherapy with the MP regimen for stage III multiple myeloma (MM) .There were randomly divided into two groups VMCP / VBAP group 42 patients, alternately using VMCP and VBAP regimen, intermittent period of 3 weeks, extended to 6 weeks after the effective.VMCP program includes vincristine 1mg intravenous 1 day, melphalan 5mg / m ~ 2 / day,